{"filing":{"accession_number":"0001193125-26-323652","cik":"0001607678","ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"vktx-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-20260729.htm"},"events":[{"id":21597,"run_id":19485,"accession_number":"0001193125-26-323652","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Viking Therapeutics issued a press release on July 29, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $115.8 million, G\u0026A expenses of $16.9 million, and a net loss of $128.0 million ($1.10 per share). The disclosure includes detailed financial highlights and a corporate update on clinical pipeline progress, which is the hallmark of an earnings release under Item 2.02.","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21277,"accession_number":"0001193125-26-323652","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Viking Therapeutics issued a press release on July 29, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $115.8 million, G\u0026A expenses of $16.9 million, and a net loss of $128.0 million ($1.10 per share). The disclosure includes detailed financial highlights and a corporate update on clinical pipeline progress, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:10:15.085457+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21277,"accession_number":"0001193125-26-323652","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Viking Therapeutics issued a press release on July 29, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $115.8 million, G\u0026A expenses of $16.9 million, and a net loss of $128.0 million ($1.10 per share). The disclosure includes detailed financial highlights and a corporate update on clinical pipeline progress, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:10:15.085457+00:00","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-07-29"}]}